Herbert Smith Freehills has appointed Chris Parker KC as Co-Head of the firm's Pharmaceuticals group.
Chris is a partner specialising in international arbitration, with specific expertise in the pharmaceutical sector. He has significant international experience, having acted as counsel and advocate in arbitrations across the world and under various governing laws and having spent 3 years in the firm's New York office, and a year in Shanghai. He has helped major pharmaceutical and biotechnology companies resolve and avoid disputes relating to royalties, IP ownership, product development and co-promotion.
Chris was appointed as Queen's Counsel (now King's Counsel) in March 2022.
Chris replaces Shaun McVicar as Co-Head. In his new role he will work alongside fellow Co-Head Alan Montgomery to help grow the firm's client relationships in the sector, to support the team and to develop and implement the firm's pharmaceuticals sector strategy.
Chris commented: "Pharmaceuticals is one of the world's most vital sectors but also one of its most innovative and fast-paced. It's a fascinating sector to work in, especially given the shifting regulatory and technology landscape. I'm really looking forward to driving the sector group forward alongside Alan to the benefit of our clients."
Alan Montgomery commented: "I've worked alongside Chris for a number of years and his deep sector knowledge, energy and experience will prove invaluable in this leadership role in the group. I'd also like to thank Shaun for his huge contribution to the firm, and to our work in the sector."
Against a backdrop of technological change and an increasing and aging population, Herbert Smith Freehills partners with clients to help them achieve their goals, capitalise on opportunities and navigate uncertainty. With scientifically qualified lawyers at the heart of the team, the firm combines technical and strategic insight to support clients as it delivers for patients.